桂龙咳喘宁品牌怎么样 申请店铺

我要投票 桂龙咳喘宁在医疗器械行业中的票数:99 更新时间:2025-02-23
桂龙咳喘宁是哪个国家的品牌?「桂龙咳喘宁」是桂龙药业(安徽)有限公司旗下著名品牌。该品牌发源于安徽省马鞍山市,由创始人Stephen John Coplin在2003-11-25期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力桂龙咳喘宁品牌出海!通过在本页面挂载桂龙咳喘宁品牌的产品链接和联系邮箱,可以提高桂龙咳喘宁产品曝光!跨境电商爆单神器,目前只要100元/年哦~

桂龙咳喘宁怎么样

桂龙咳喘宁,知名咳嗽药品牌,成立于1989年,高新技术企业,中药呼吸系统和咽喉品类领域领先企业,集研发/生产/销售于一体的中药企业


桂龙药业成立于1989年,是集研发、生产、销售为一体的中药行业企业。桂龙,取自谐音“贵”“隆”,意为富贵华荣兴旺发达。且“桂”,有桂树四季翠绿,香飘万里而古朴典雅,是传统中药的化身;“龙”,象征着东方文化与蓄势勃发的力量。

公司拥有员工约1000人,总部位于福建省厦门市,在安徽省马鞍山市和山西省忻州市设有两个生产基地,总占地面积11万平方米,建筑面积近4万平方米,均为现代化的花园式GMP工厂。 桂龙药业在全国设立27个销售办事处,拥有500人的销售团队,销售人员有效管理近6万家零售终端门店,产品覆盖全国近三十万家零售药店,以及全国所有主流连锁药店。

2003年经当涂县委、县人大招商引资在当涂经济开发区征地120亩,投资5000万元,建立了一座符合GMP要求的生产企业——桂龙药业(安徽)有限公司。公司目前拥有国药准字号品种31个,主要生产经营范围为:片剂、胶囊剂、颗粒剂、煎膏剂、及生产加工、经营糖果。其主导产品主要有:慢严舒柠牌清喉利咽颗粒、桂龙咳喘宁胶囊、新生化颗粒、复方柴胡安神颗粒、好爽糖等。科技创新、管理创新、岗位创新、市场创新是企业发展的原动力。科技人员占员工比例36%以上。公司拥有的技术研发中心和检测中心,保障了公司科技的可持续发展,保障了药品的质量和药品的安全。

桂龙专注于中药呼吸系统和咽喉品类领域,创立了国内呼吸系统和咽喉领域两个品牌“桂龙”牌、“慢严舒柠”牌。

“有健康就有桂龙,桂龙药业、健康事业”是桂龙药业的宗旨;品牌战略、人才战略、创新战略是桂龙发展的三个支撑;“敬业”、“诚信”、“责任”、“创新”是桂龙发展的核心理念。随着企业的发展壮大,桂龙药业现有的生产与研发平台不足以支撑桂龙药业未来若干年的迅速持续发展,为此桂龙药业决定在当涂经开区征地数百亩,以国内专业的制药技术和工艺装备,打造一个集生物医药生产和研究开发于一体的现代化医药产业园,以此支撑桂龙未来十多年的长足发展和技术创新、科技进步。


Guilong Kechuanning, a famous cough medicine brand, was founded in 1989. It is a high-tech enterprise, a leading enterprise in the field of traditional Chinese medicine respiratory system and throat category. Guilong pharmaceutical, a traditional Chinese medicine enterprise integrating R & D, production and sales, was founded in 1989. It is a traditional Chinese Medicine enterprise integrating R & D, production and sales. Guilong, from the homonym "Gui" and "long", means prosperity and prosperity. And "Gui" is the embodiment of traditional Chinese medicine, which has four seasons of green, fragrant and elegant, and "long" symbolizes the power of Oriental culture and vigorous development. The company has about 1000 employees and its headquarter is located in Xiamen City, Fujian Province. It has two production bases in Maanshan City, Anhui Province and Xinzhou City, Shanxi Province, covering a total area of 110000 square meters and a building area of nearly 40000 square meters, all of which are modern garden GMP factories. Guilong pharmaceutical has 27 sales offices in China, with a sales team of 500 people. The sales staff effectively manage nearly 60000 retail terminal stores, covering nearly 300000 retail pharmacies and all mainstream chain pharmacies in China. In 2003, Dangtu County Party committee and County People's Congress invested 120 mu of land in Dangtu economic development zone and invested 50 million yuan to establish a GMP compliant production enterprise - Guilong Pharmaceutical (Anhui) Co., Ltd. At present, the company has 31 varieties of State Pharmaceutical quasi brand, the main production and business scope are: tablets, capsules, granules, decoctions, as well as the production, processing and operation of candy. Its main products are: Manyan shuning brand Qinghou Liyan granules, Guilong Kechuanning capsule, xinbiochemical granules, compound Bupleurum Anshen granules, haoshuangtang, etc. Technological innovation, management innovation, post innovation and market innovation are the driving force of enterprise development. Science and technology personnel account for more than 36% of employees. The technology R & D center and testing center of the company ensure the sustainable development of the company's science and technology and the quality and safety of drugs. Focusing on the field of respiratory system and throat category of traditional Chinese medicine, Guilong has established two domestic brands in the field of respiratory system and throat, "Guilong" brand and "slow, strict, shuning" brand. The aim of Guilong pharmaceutical industry is to "have health, Guilong pharmaceutical industry and health cause"; brand strategy, talent strategy and innovation strategy are the three supports for the development of Guilong; dedication, integrity, responsibility and innovation are the core concepts for the development of Guilong. With the development of enterprises, the existing production and R & D platform of Guilong pharmaceutical industry is not enough to support the rapid and sustainable development of Guilong pharmaceutical industry in the next few years. Therefore, Guilong pharmaceutical industry decided to take hundreds of mu of land in Dangtu Economic Development Zone to build a modern pharmaceutical industrial park integrating biological pharmaceutical production and research and development with domestic professional pharmaceutical technology and process equipment, so as to support Guilong pharmaceutical industry Long's considerable development and technological innovation and scientific and technological progress in the next ten years.

本文链接: https://brand.waitui.com/0d765d197.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

恒瑞医药:羟乙磺酸达尔西利片联合内分泌治疗乳腺癌III期临床试验达主要终点

36氪获悉,恒瑞医药公告称,公司自主研发的羟乙磺酸达尔西利片在激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性女性乳腺癌辅助治疗的III期临床试验中,首次期中分析主要终点达到统计学显著性。研究结果显示,达尔西利联合内分泌治疗可显著降低患者复发风险,提高患者无侵袭性疾病生存期(IDFS)。公司已向国家药品监督管理局药品审评中心递交上市前沟通交流申请。该药品是公司自主研发的化学药品1类新药,是一种口服、高效、选择性的小分子CDK4/6抑制剂。

59分钟前

深圳:近期将发布人形机器人专项政策 在全市科技重大专项中安排人工智能和机器人专项

深圳市政府新闻办2月23日召开“打造最好科技创新生态和人才发展环境”主题新闻发布会。市人工智能产业办主任林毅在会上表示,深圳在人工智能和机器人领域基础雄厚、未来可期。下一步,我们将在政策、场景、创新、机器人四个方面持续发力。此外,近期我们还将发布人形机器人专项政策,通过“揭榜挂帅”等方式,对开放应用场景、突破关键技术、构建专用数据集、提升规模化制造和应用能力等予以精准支持。同时,还将在全市科技重大专项中安排人工智能和机器人专项,鼓励产、学、研、用组成创新联合体进行协同攻关。(财联社)

59分钟前

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

59分钟前

2025年中央一号文件发布

36氪获悉,2025年中央一号文件2月23日发布,《中共中央 国务院关于进一步深化农村改革 扎实推进乡村全面振兴的意见》提出,以改革开放和科技创新为动力,巩固和完善农村基本经营制度,深入学习运用“千万工程”经验,确保国家粮食安全,确保不发生规模性返贫致贫,提升乡村产业发展水平、乡村建设水平、乡村治理水平,千方百计推动农业增效益、农村增活力、农民增收入,为推进中国式现代化提供基础支撑,这是党的十八大以来第13个指导“三农”工作的中央一号文件。

59分钟前

海天味业:公司发行H股备案申请材料获中国证监会接收

36氪获悉,海天味业公告称,公司已于2025年1月13日向香港联交所递交了发行H股股票并在香港联交所主板挂牌上市的申请。公司已向中国证监会报送了关于公司本次发行的备案申请材料并于近日获中国证监会接收。该事项仍存在不确定性,公司将根据进展情况及时履行信息披露义务。

59分钟前

本页详细列出关于海氏海诺的品牌信息,含品牌所属公司介绍,海氏海诺所处行业的品牌地位及优势。
咨询